WATCHLONGEVITY

Saturday, June 20, 2026

STAT+: AstraZeneca’s GLP-1 pill shows promise in obesity, diabetes trials
DEVELOPING
Importance
62
Trust
71
Urgency
65
CLINICAL TRIAL

STAT+: AstraZeneca’s GLP-1 pill shows promise in obesity, diabetes trials

AstraZeneca tested a pill form of GLP-1 (a weight-loss and diabetes drug) in mid-stage trials and saw promising results. The company doesn't yet know how well it works compared to other pill versions on the market.

Analysis

AstraZeneca's oral GLP-1 pill showed promise in mid-stage trials. It adds a new rival in the race to make a weight-loss pill, but head-to-head data vs other pills isn't available yet.

  • AstraZeneca tested a pill form of GLP-1 in mid-stage trials for obesity and diabetes
  • Results described as promising based on trial data
  • Company has not compared its pill to other oral GLP-1 drugs on the market
glp-1AstraZeneca
STAT News — Pharma12d
Read